Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128243 | 1.00 | CTSS (0.38) | CTSSCTSKAAK1MMP13KMT2A | |
| SCHEMBL67050 | 1.00 | CTSS (0.38) | CTSSCTSKAAK1MMP13KMT2A | |
| SCHEMBL31703376 | 1.00 | CTSS (0.38) | CTSSCTSKAAK1MMP13KMT2A | |
| SCHEMBL27645074 | 1.00 | CTSS (0.38) | CTSSCTSKAAK1MMP13KMT2A | |
| SCHEMBL1486202 | 1.00 | CTSS (0.38) | CTSSCTSKAAK1MMP13KMT2A | |
| SCHEMBL8460615 | 0.87 | CA2 (0.34) | CTSSCTSKAAK1MMP13KMT2A | |
| SCHEMBL10273899 | 0.87 | AAK1 (0.32) | AAK1MMP13KMT2AMEN1GAA | |
| SCHEMBL28760575 | 0.85 | CTSS (0.38) | CTSSCTSKKMT2AMEN1GAA | |
| SCHEMBL11661957 | 0.85 | CTSS (0.38) | CTSSCTSKKMT2AMEN1GAA | |
| SCHEMBL11661955 | 0.85 | CTSS (0.38) | CTSSCTSKKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| CN-109475592-B | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | 伊莱利利公司 | 2022-08-09 | — | — | CN | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| EP-1957518-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-9067881-B2 | 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives | NOVARTIS AG (CH) | 2015-06-30 | — | — | US | disclosed |
| EP-2668159-A1 | 4-TOLYL-ETHYNYL-OCTAHYDRO-INDOLE-1-ESTER DERIVATIVES | Novartis AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-20130303538-A1 | 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives | NOVARTIS PHARMA AG (CH) | 2013-11-14 | — | — | US | disclosed |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | PHARMATROPHIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| EP-1599471-A1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | Astrazeneca AB (SE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004078753-A1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | WO | disclosed |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1333025-A1 | CYANOPYRROLIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-6117841-A | USED TO TREAT STROKE, CEREBRAL ISCHEMIA, PAIN, HEAD TRAUMA OR EPILEPSY | WARNER-LAMBERT COMPANY (US) | 2000-09-12 | — | — | US | disclosed |
| WO-1998054123-A1 | SUBSTITUTED PEPTIDYLAMINE CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
| EP-0564924-B1 | 2-Oxoethyl derivatives as immunosuppressants | BAYER AG (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5686424-A | FOR TREATING INFLAMMATION | MILES INC. (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1997005126-A1 | MUPIROCINSULFAMATES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-02-13 | — | — | WO | disclosed |
| EP-0564924-A2 | 2-Oxoethyl derivatives as immunosuppressants | Bayer Corporation (US) | 1993-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303538-A1 | 4-Tolyl-ethynyl-octahydro-indole-1-ester derivatives | TPH1, IDO1, TPH2 | CTSS 3602/4885CTSK 3789/4885AAK1 1904/4885 |
| US-20040072892-A1 | Cyanopyrrolidine derivatives | CCR9, OPRD1, CBR1 | CTSS 3839/4885CTSK 3996/4885AAK1 3823/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CTSS 4022/4885CTSK 4661/4885AAK1 4583/4885 |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | CTSS 972/4885CTSK 1045/4885AAK1 3603/4885 |
| US-20120322799-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | CTSS 972/4885CTSK 1045/4885AAK1 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.